Literature DB >> 356235

Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial.

A Ruotsi, U Vainio.   

Abstract

Eighteen patients (11 men and 7 women) suffering from primary or secondary gout, were treated with either proquazone or indomethacin for acute attacks in a double-blind study. There were 9 patients in each treatment group. A marked improvement of clinical symptoms appeared in 2-3 days. In the proquazone group, complete remission was achieved in 6 patients, a good result in one, and a slight improvement in one patient, whereas one patient did not respond to treatment. The corresponding figures for the indomethacin group were 4 cases with complete remission, 4 with a good result, and one not responding to treatment. A significant decrease in s-uric acid values was noted in the proquazone group. In this group too, mild gastrointestinal symptoms appeared in 2 patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 356235     DOI: 10.3109/03009747809095668

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  11 in total

Review 1.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 2.  The challenges of gout management in the elderly.

Authors:  Lisa K Stamp; Sarah Jordan
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

3.  Comparison of the natural history of untreated acute gouty arthritis vs acute gouty arthritis treated with non-steroidal-anti-inflammatory drugs.

Authors:  M H Arnold; S J Preston; W W Buchanan
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 4.  Outcome measures in acute gout: a systematic literature review.

Authors:  Nicola Dalbeth; Cathy S Zhong; Rebecca Grainger; Dinesh Khanna; Puja P Khanna; Jasvinder A Singh; Fiona M McQueen; William J Taylor
Journal:  J Rheumatol       Date:  2013-12-15       Impact factor: 4.666

5.  Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid.

Authors:  S Tiitinen; M Nissilä; H M Ruutsalo; H Isomäki
Journal:  Clin Rheumatol       Date:  1983-09       Impact factor: 2.980

Review 6.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

Review 7.  Management of acute and chronic gouty arthritis: present state-of-the-art.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.

Authors:  H Ralph Schumacher; Judith A Boice; David I Daikh; Saurabh Mukhopadhyay; Kerstin Malmstrom; Jennifer Ng; Guillermo A Tate; Javier Molina
Journal:  BMJ       Date:  2002-06-22

Review 9.  Proquazone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states.

Authors:  S P Clissold; R Beresford
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

Review 10.  Overview of the management of acute gout and the role of adrenocorticotropic hormone.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.